Integra LifeSciences Holdings Corporation reported $415.6 million in sales and ($512.674) million in operating losses for the quarter ending June 30, 2025. The revenue came in stronger than analysts expected, and the EPS was slightly higher than predicted.
| Integra LifeSciences Holdings Corporation 2025 Report ($000s): 3 Months Ended 06/30/25 | ||||||
| 3 Month Sales | 6 Month Sales | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| $418,175 | $415,605 | -0.61% | $787,047 | $798,258 | 1.42% | |
| Op Profit | Op Profit | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| -$3,029 | -$512,674 | -16826% | $935 | -$528,171 | -56589% | |
| -1% | -123% | 0% | -66% | |||
| EPS | EPS | |||||
| 2024 | 2025 | % Change | 2024 | 2025 | % Change | |
| -$0.16 | -$6.31 | -3844% | -$0.20 | -$6.65 | -3225% | |
| 2026 Sales Estimate | 2025 Sales Estimate | |||||
| Consensus | Change | Consensus | Change | |||
| $1,750,000 | 4.16% | $1,680,000 | 4.34% | |||
Source: RRY Publications LLC
For most companies, reporting $415.6 million in sales alongside a half-billion-dollar operating loss would trigger an emergency board retreat, a CFO “resignation to spend more time with family,” and an on-site espresso machine running 24/7. For Integra LifeSciences, it’s apparently just another step in a carefully choreographed transformation dance.
The July 30, 2025 call with analysts had President & CEO Mojdeh Poul and CFO Lea Knight steering the narrative with equal parts confidence and compliance jargon. Poul, sounding every bit the corporate turnaround architect, assured investors:
“Our transformation is underway…establishing the foundation for operational excellence…and a culture of continuous improvement…”
Translation: The check engine light is still on, but we’ve finally bought the right repair manual.
The Compliance Master Plan — and Why It’s the Star of the Show
If you’re picturing a leather-bound corporate manifesto, think again. The Compliance Master Plan is Integra’s FDA-centric playbook to get its manufacturing house in order. Assessments of internal plants wrapped up ahead of schedule, remediation is in progress, and the Braintree facility—site of past quality headaches—is reportedly showing signs of life.
Even better for surgeons waiting on specialty biologics, the long-grounded SurgiMend and PriMatrix are inching toward relaunch. Poul hinted that while some remediation will bleed into 2026, the risk of fresh FDA holds this year is “not material.”
Revenue guidance got a slight polish—$1.655 to $1.68 billion for 2025—and full-year EPS expectations remain steady at $2.19 to $2.29.
Analyst Q&A: Reading Between the Lines
Vikramjeet Chopra (Wells Fargo) wanted to know why third-quarter EPS guidance dipped while the full-year range didn’t budge. Knight’s answer boiled down to this:
- Q3 revenue will look a lot like Q2 (which was…flat).
- Q4 will see a $38 million bump, 60% from seasonal demand and Integra Skin momentum, 40% from supply recovery.
Young Li (Jefferies) asked the million-dollar question: How fast can you win back customers after supply chaos? Knight’s response was cautiously upbeat—ship hold recoveries are going smoothly, but for products like PriMatrix and SurgiMend, regaining market share will require “lift.” (Translation: competitor reps aren’t exactly standing still.)
Why Orthopedic Execs Should Care
If you run a medtech company—or compete with one—Integra’s situation is a case study in how operational compliance can dominate corporate strategy. Every hour Poul’s “transformation and program management office” spends on remediation is an hour not spent on R&D or aggressive market expansion.
The lesson? In orthopedics, regulatory friction doesn’t just slow you down—it defines your tempo. And in Integra’s case, the metronome is set to “compliance allegro.”
Still, if they can pull off the supply recovery, relaunch dormant product lines, and keep the FDA happy, Integra could enter 2026 not as a turnaround story—but as a survivor story. And in medtech, survival is the necessary step to market recovery.
